Antimicrobial resistance diagnostics market seen reaching $6.23 billion by 2030

The antimicrobial resistance diagnostics market is projected to rise from $4.74 billion in 2026 to $6.23 billion by 2030, driven by rising drug-resistant infections, faster molecular testing and stronger AMR surveillance. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Antimicrobial resistance diagnostics help identify pathogens that no longer respond to antibiotics or other antimicrobials. - Faster detection can guide targeted treatment and reduce unnecessary broad-spectrum antibiotic use. - The market’s growth reflects rising pressure on healthcare systems from drug-resistant infections and the need for better surveillance.

What happened: - The Business Research Company published a 2026 report on the antimicrobial resistance diagnostics market. - The market is estimated at $4.74 billion in 2026, up from $4.41 billion in 2025. - The report projects the market will reach $6.23 billion by 2030. - The report also cites a 7.5% CAGR from 2025 to 2026 and a 7.1% CAGR through 2030. - The report was issued July 25, 2026. - A free sample is available here. - The full report is available here.

The details: - Growth through 2026 is tied to rising antibiotic-resistant infections, continued use of culture-based diagnostics, more hospital-acquired infections, greater antimicrobial stewardship awareness and expansion of clinical microbiology labs. - Growth through 2030 is expected to be supported by PCR and next-generation sequencing advances, government funding for AMR surveillance, stronger demand for rapid tests, more pharmaceutical and biotech research and data-driven decision support tools. - Key trends include wider use of point-of-care AMR diagnostics, more personalized antimicrobial therapies, intensified surveillance of drug-resistant pathogens, growth in molecular and genomic testing and stronger infection control and stewardship efforts. - AMR diagnostics identify the exact pathogen and determine which drugs it is resistant or sensitive to. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report says 2026 editions now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables.

Between the lines: - The market outlook suggests diagnostics are moving from a support function to a core tool in antimicrobial stewardship and treatment selection. - The combination of rapid molecular testing and surveillance funding points to demand for faster clinical decisions and better public-health tracking. - The projected growth also signals that resistance is becoming a bigger commercial opportunity for diagnostic vendors as infection rates rise. - In November 2024, the UK Health Security Agency reported serious antibiotic-resistant infections in England rose from 58,224 cases in 2022 to an estimated 66,730 in 2023, while antibiotic use reached 2.4% in 2023.

What's next: - North America remained the largest regional market in 2025. - Asia-Pacific is projected to grow the fastest during the forecast period. - Wider adoption of point-of-care testing and genomic diagnostics is likely to shape the next phase of market competition. - Infection control, stewardship programs and AMR surveillance are likely to stay central to demand.

The bottom line: - Antimicrobial resistance diagnostics are expected to keep growing as hospitals, labs and public-health agencies look for faster ways to detect resistant infections and limit their spread.